Filing Details
- Accession Number:
- 0000950170-25-042726
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2025-03-20 16:36:03
- Reporting Period:
- 2025-03-18
- Filing Date:
- 2025-03-20
- Accepted Time:
- 2025-03-20 16:36:03
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1841387 | Candel Therapeutics Inc. | CADL | Biological Products, (No Disgnostic Substances) (2836) | 522214851 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1909680 | Francesca Barone | C/O Candel Therapeutics, Inc. 117 Kendrick St., Suite 450 Needham MA 02494 | Chief Scientific Officer | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2025-03-18 | 18,000 | $1.55 | 128,673 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2025-03-18 | 32,146 | $8.76 | 96,527 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2025-03-18 | 18,000 | $0.00 | 18,000 | $1.55 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 30,822 | 2030-12-30 | No | 4 | M | Direct |
Footnotes
- This transaction reported on this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on 11/22/2024.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.345 to $9.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 herein.
- 25% of the shares underlying this option vested and became exercisable on December 30, 2021, with the remainder vesting in thirty-six equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
Billionaire Hedge Funds
